Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies

Open access
Cai, Mu-Yan, Tong, Zhu-Ting, Zheng, Fang, Liao, Yi-Ji, Wang, Yi, Rao, Hui-Lan, Chen, Yang-Chao, Wu, Qiu-Liang, Liu, Yan-Hui, Guan, Xin-Yuan, Lin, Marie C, Zeng, Yi-Xin, Kung, Hsiang-Fu, Xie, Dan·2011·Gut

Abstract

Background and aims: A previous study of ours indicated that enhancer of zeste homologue 2 (EZH2) plays an important role in hepatocellular carcinoma (HCC) tumorigenesis. The aim of the present study was to investigate the potential diagnostic utility of EZH2 in HCC. Methods: Immunohistochemistry was performed to examine the expression dynamics of EZH2 in two independent surgical cohorts of HCC and non-malignant liver tissues to develop a diagnostic yield of EZH2, HSP70 and GPC3 for HCC detection. The diagnostic performances of EZH2 and a three-marker panel in HCC were re-evaluated by using an additional biopsy cohort. Results: Immunohistochemistry analysis demonstrated that the sensitivity and specificity of EZH2 for HCC detection was 95.8% and 97.8% in the testing cohort. Similar results were confirmed in the validation cohort. For diagnosis of well-differentiated HCCs, the sensitivity and specificity were 68.9% and 91.5% for EZH2, 62.5% and 98.5% for HSP70, 50.0% and 92.1% for GPC3, and 75.0% and 100% for a three-marker panel. In biopsies, positive cases for at least one marker increased from large regenerative nodule and hepatocellular adenoma (0/12) to focal nodular hyperplasia (2/20), dysplastic nodule (7/25), well-differentiated HCC (16/18) and moderately and poorly differentiated HCC (54/54). When at least two positive markers were considered, regardless of their identity, the positive cases were detected in 0/12 large regenerative nodules and hepatocellular adenomas, 0/20 focal nodular hyperplasias, 0/25 dysplastic nodules, 11/18 well-differentiated HCCs, 32/37 moderately differentiated HCCs and 15/17 poorly differentiated HCCs. Conclusion: Our findings suggest that EZH2 protein, as examined by immunohistochemistry, may serve as a promising diagnostic biomarker of HCCs, and the use of a three-marker panel (EZH2, HSP70 and GPC3) can improve the rate of detection of HCCs in liver biopsy tissues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gut.2010.231993

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 160

Metadata

Authors
Cai, M.-Y., Tong, Z.-T., Zheng, F., Liao, Y.-J., Wang, Y., Rao, H.-L., Chen, Y.-C., Wu, Q.-L., Liu, Y.-H., Guan, X.-Y., Lin, M. C., Zeng, Y.-X., Kung, H.-F., & Xie, D.
Venue
Gut
Publisher
BMJ
Published
2011-02-17
Volume
60
Issue
7
Pages
967-976
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2105154348
Cited by
160
References
2
FWCI
7.55
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. https://app.cochat.ai/papers/10.1136/gut.2010.231993
The paper
Cai, M.-Y., Tong, Z.-T., Zheng, F., Liao, Y.-J., Wang, Y., Rao, H.-L., Chen, Y.-C., Wu, Q.-L., Liu, Y.-H., Guan, X.-Y., Lin, M. C., Zeng, Y.-X., Kung, H.-F., & Xie, D. (2011). EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut. https://doi.org/10.1136/gut.2010.231993

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.